Saterinone
CAS: 102669-89-6
Ref. 3D-CEA66989
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Informação sobre produto
- Saterinone [INN]
- (+-)-1,2-Dihydro-5-(p-(2-hydroxy-3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-6-methyl-2-oxonicotinonitrile
- Saterinona
- Saterinona [Spanish]
- Saterinonum
- Saterinonum [Latin]
- Unii-W4P85Fo7Gs
- 5-(4-{2-Hydroxy-3-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Propoxy}Phenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carbonitrile
Saterinone is a cardiac glycoside that binds to the beta-adrenergic receptor. Saterinone has been shown to reduce the incidence of cancer and bowel disease in rats, as well as the severity of bowel disease. It is also used for the treatment of congestive heart failure and inflammatory bowel disease. This drug has inhibitory properties on isolated heart muscle cells, which are mediated by its ability to bind to the beta-adrenergic receptor. Furthermore, saterinone may have a role in blood pressure monitoring because it inhibits angiotensin II-induced contraction of isolated vascular smooth muscle cells.
Saterinone is an inhibitor of nitroprusside-induced hypotension in rabbits, which may be due to its ability to inhibit nitric oxide synthase (NOS).
Propriedades químicas
Consulta técnica sobre: 3D-CEA66989 Saterinone
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
